At Omnicure Clinical Research, we stay at the forefront of medical innovation — following breakthroughs that bring new hope to patients and families worldwide.
Understanding COPD
Chronic Obstructive Pulmonary Disease (COPD) is far more than a “chronic cough” or occasional shortness of breath — it’s a progressive inflammatory disease that affects the quality of life for millions of people across the globe.
COPD includes lung conditions such as chronic bronchitis and emphysema, both of which cause airflow obstruction and persistent symptoms — coughing, mucus production, fatigue, and difficulty breathing — that worsen over time.
Exacerbations (sudden flare-ups) can accelerate lung damage and often lead to hospitalizations. Traditional treatments include bronchodilators, inhaled corticosteroids, and pulmonary rehabilitation.
But what happens when patients still struggle to control their symptoms despite standard therapies? This is where science, innovation, and personalized medicine intersect.
GSK Innovation: Opening the Door to a New Approach
GSK has made remarkable strides in developing therapies that go beyond conventional COPD treatment — especially for patients with specific inflammatory profiles.
- Nucala (mepolizumab): The FDA recently accepted for review an expanded indication for use in COPD patients who exhibit an eosinophilic phenotype — meaning they show certain markers of type 2 inflammation.
Sources: gsk.com - Clinical studies, including the MATINEE trial, demonstrated a significant reduction in moderate to severe exacerbations when mepolizumab was added to standard inhaled therapy compared with placebo.
Sources: BioSpace, BioPharmaDive, gsk.com - Trelegy Ellipta: Another GSK innovation, this once-daily triple combination inhaler (inhaled corticosteroid + bronchodilators) simplifies treatment, offering convenience and improved adherence.
Sources: gskpro.com, gskusmedicalaffairs.com
Together, these innovations mark a shift toward personalized medicine — identifying which COPD patients may benefit most from targeted biological therapies beyond traditional inhalers.
What This Means for Patients
1. More Personalized Treatment
Not all COPD patients have the same inflammatory profile. Biomarkers, such as blood eosinophil counts, help identify who may respond best to biologic therapies like mepolizumab.
2. Fewer Exacerbations = Better Quality of Life
Each flare-up or hospitalization can permanently damage lung tissue. Reducing the number and severity of these episodes helps preserve lung function and improves day-to-day wellbeing.
3. Simplified Care and Improved Adherence
Single-device regimens and therapies requiring less frequent dosing can increase adherence, empowering patients to stay consistent with their full treatment plans.
4. Accessibility and Cost Control
In the U.S., GSK has announced plans to cap out-of-pocket costs for asthma and COPD inhalers — a major step toward affordability and equitable access for patients.
A Future of Breathing Easier
COPD is a complex condition that demands strategies beyond traditional treatments. GSK’s continued innovation — particularly the potential expansion of mepolizumab for select COPD patients — represents a promising paradigm shift toward more personalized, effective care.
At Omnicure Clinical Research, we are proud to contribute to the advancement of respiratory studies that bring hope to those living with COPD. Through collaboration with leading sponsors and CROs, and the dedication of our experienced investigators, we continue to expand access to groundbreaking therapies that help patients breathe easier and live better.
Join Our Current COPD Studies
At Omnicure Clinical Research, we are currently conducting two COPD studies in collaboration with GSK, focused on helping patients breathe better and live healthier lives.
If you or someone you love has been diagnosed with Chronic Obstructive Pulmonary Disease (COPD), you may qualify to participate.
Our team is actively recruiting participants through 2028.
Call us today at (305) 842-2000 to learn more and find out if you or your loved one may be a good candidate to take part in one of our COPD studies.
Together, we can advance science — and bring hope to every breath.
